Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00050076 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.

A Phase 2 study of Congestive Heart Failure, sponsored by Takeda.

Completed
Registry status
Phase 2
Development phase
204
Enrollment target
20
Study locations

NCT00050076 is a Phase 2 study of Congestive Heart Failure that has completed, run by Takeda. The registered enrollment target is 204 participants, below the 326-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00050076, a Phase 2 study of Congestive Heart Failure, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 2
Development phase
204 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine the effect of two different doses of MCC-135, once daily (QD) or twice daily (BID), on the disease state and the quality of life in subjects with congestive heart failure.

Conditions Studied

Congestive Heart Failure

Interventions

  • DRUG Placebo
  • DRUG MCC-135

Study Locations (20)

California

  • Capitol Intervention Cardiology - Carmichael
  • San Diego Cardiovascular - Encinitas
  • LAC & USC Medical Center - Los Angeles
  • ARI Clinical Trials, Inc Arrhythmia Research & Cardiology Health Center - Redondo Beach
  • Clinical Trials Research - Roseville
  • Sacramento Heart & Vascular Medical Associates - Sacramento
  • University of California San Diego - San Diego
  • Apex Research Institute - Santa Ana

Florida

  • Cardiology Consultants PA - Daytona Beach
  • Cardiology Associates of Fort Lauderdale - Fort Lauderdale
  • Jacksonville Center for Clinical Research - Jacksonville
  • Cardiovascular Center of Sarasota - Sarasota

Arizona

  • Maricopa Medical Center - Phoenix
  • University of Arizona Medical Center - Tucson

Kentucky

  • Medical Center Cardiologist - Louisville
  • Louisville Cardiology Medical Group, PSC - Louisville

Louisiana

  • Louisiana Heart Center - Chalmette
  • New Orleans Center for Clinical Research - New Orleans

Georgia

  • Southern Clinical Research & Management - Augusta

Indiana

  • Medical Group of Fort Wayne, PC - Fort Wayne

Trial Details

FieldValue
Enrollment Target 204 participants
Start Date 2002-08
Est. Completion 2003-08
Phase Phase 2

Sponsor

Takeda

408 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00050076

The ClinicalTrials.gov registry entry for NCT00050076 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 326-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (37% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Congestive Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00050076 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT00050076 about?

NCT00050076 is a clinical study titled "Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.". The purpose of this study is to determine the effect of two different doses of MCC-135, once daily (QD) or twice daily (BID), on the disease state and the quality of life in subjects with congestive heart failure.

What is the current status of trial NCT00050076?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2002-08. Estimated completion is 2003-08.

What conditions does trial NCT00050076 study?

This clinical trial studies the following conditions: Congestive Heart Failure.

What interventions are being tested in trial NCT00050076?

The interventions under investigation include: Placebo (DRUG), MCC-135 (DRUG).

Who is sponsoring clinical trial NCT00050076?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00050076 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Congestive Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Congestive Heart Failure

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.